newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

  • IGC Pharma announced the addition of Kerwin Medical Center in Dallas, Texas as a new clinical site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's disease.
  • The company reported approximately 80% enrollment in the CALMA trial as it advances through the final phase of recruitment.
  • Kerwin Medical Center brings specialized behavioral neurology expertise & experience in neurodegenerative conditions to support consistent execution & patient access.
  • Dr. Alka Khera serves as the Principal Investigator at the new site, leveraging her background in behavioral neurology to enhance clinical rigor.
  • The site is part of the Pinnacle Network & focuses on patient participation & retention in dementia-related trials through community-based engagement.
  • CEO Ram Mukunda stated the addition strengthens the CALMA network's ability to execute efficiently & generate robust data as the trial nears enrollment completion.
  • IGC Pharma utilizes AI to accelerate drug discovery & optimize clinical trials for its lead asset IGC-AD1, alongside pipeline programs including TGR-63 & early-stage neurodegeneration & metabolic programs.
  • The press release includes standard forward-looking statements warning that actual results may differ due to risks regarding enrollment, safety, efficacy, & regulatory approvals.